SEC Form 4 · accession 0001209191-18-048571
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Gorlin
Director
Period of report
Aug 23, 2018
Accepted (ET)
Aug 27, 2018 · 7:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326110
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 23, 2018 | S | 21,475 | $3.0598 | D | 224,805 | D | |
| Common StockF2 | Aug 24, 2018 | S | 10,225 | $3.0651 | D | 214,580 | D | |
| Common StockF3 | Aug 27, 2018 | S | 18,300 | $3.0854 | D | 196,280 | D | |
| Common Stock | holding | — | — | — | 321,720 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average share price of an aggregate total of 21,475 shares sold in the price range of $3.03 to $3.105 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2Represents the weighted average share price of an aggregate total of 10,225 shares sold in the price range of $3.04 to $3.11 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average share price of an aggregate total of 18,300 shares sold in the price range of $3.05 to $3.14 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.